Novo Nordisk is a global healthcare company with more than 87 years of innovation and achievement in diabetes care. Our commitment to research is reflected in our full portfolio of diabetes pharmaceuticals and delivery devices and the many new treatment options in our pipeline.
The story begins with Nobel-prize winning physiologist Dr. August Krogh and his belief that anyone who suffered from diabetes, including his wife Marie, should have access to insulin.
Inspired by his wife, Dr. Krogh founded Nordisk Insulinlaboratorium in 1923 and marketed the first insulin for patients. Marie was the first beneficiary—and Novo Nordisk’s first patient.
Two years later, another company - Novo Terapeutisk Laboratorium - was born, and began producing "Insulin Novo" and a unique syringe.
Over the decades, these two companies grew to be global leaders in insulin production and other areas. In January 1989, Novo and Nordisk joined forces to become the new company called Novo Nordisk.
At Novo Nordisk, our highest priority is the health and well being of patients. We are actively working to change the course of the diabetes pandemic by advancing the health care agenda to ensure patients experience quality care and treatment.
We are actively working to change the course of the diabetes pandemic, help patients living with diabetes and to expand the possibilities for people with hemophilia. Innovation and personal passsion the hallmarks of how we operate.
To learn more please visit the Novo Nordisk website.
